Address
OrbiMed Advisors LLC
767 Third Avenue
30th Floor
New York, NY 10017
United States
Phone
Website
Recent investment activity
KANDO id: 29979
Corporate information
Founders
Official name
OrbiMed Advisors Limited Liability Company
Registration country
Company type
American investment firm focused on making public and private investments in the healthcare and biotechnology industries.Overview
OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.
Funds managed
| Fund | Type | Vintage | Currency | Committed capital | IRR | x |
|---|---|---|---|---|---|---|
| OrbiMed Private Investments VII | 2017 | |||||
| OrbiMed Private Investments VI LP | 2015 | |||||
| Orbimed Global Healthcare Associates Fund LP | Hedge fund | 2014 | ||||
| OrbiMed Global Healthcare Fund LP | Hedge fund | 2014 | ||||
| OrbiMed Global Healthcare Fund Ltd | Hedge fund | 2013 | ||||
| OrbiMed Healthcare Investments Fund (Offshore) LP | 2013 | USD | 29,575,000 | |||
| OrbiMed Private Investments V LP | 2013 | |||||
| OrbiMed Private Investments IV LP | Venture | 2009 | 45.20 % | 2.78 x | ||
| OrbiMed Private Investments III LP | Venture | 2006 | 21.30 % | 2.54 x | ||
| OrbiMed Partners II LP | Hedge fund | 1998 | ||||
| OrbiMed Partners LP | Hedge fund | 1993 | ||||
| OrbiMed Healthcare Investments Trust | ||||||
| OrbiMed Royalty Opportunities II LP |
Funding rounds
Investment preferences
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 114| Company | Profile | Country | Date Sort ascending | Funding | ||
|---|---|---|---|---|---|---|
|
Blossomhill Therapeutics Inc | Biotechnology company focused on oncology and autoimmune disorders. | Series A Initial investment | |||
|
Armo BioSciences Inc | Late-stage immuno-oncology company. | Series C-1 Follow-on investment | |||
|
Nutrinia Ltd | Developer of an oral formulation of insulin for intestinal malabsorption in preterm newborns and SBS in infants. | Series D Follow-on investment | |||
|
Tricida Inc | Series C Follow-on investment | ||||
|
|
Tricida Inc | Series B Follow-on investment led the round | ||||
|
|
Tricida Inc | Series A led the round | ||||
|
Natera Inc | Biotechnology company providing preconception and prenatal genetic testing services. | Venture Initial investment led the round | |||
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series F | |||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Cleave Biosciences Inc | Drug development company focused on novel targets in cellular protein homeostasis pathways | Series A | |||
|
|
Ambit Biosciences Inc | A biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer. | Series D | |||
|
Complete Genomics Inc | Series E | ||||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series E Follow-on investment | |||
|
|
Selecta Biosciences Inc | A biotechnology company developing a new class of synthetic nanoparticle vaccines. | Series C | |||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series D Follow-on investment | |||
|
Adimab LLC | Developer of a human antibody discovery platform in yeast. | Series D | |||
|
|
Complete Genomics Inc | Series D | ||||
|
|
Amnis Corp | A biotechnology company developing high throughput laboratory automation tools that use a novel molecule detection technology. | Series D | |||
|
|
ARYx Therapeutics Inc | N/A Initial investment | ||||
|
|
Biolex Therapeutics Inc | Series D | ||||
|
|
Innovative Spinal Technologies Inc | Spine technology company. | Series C | |||
|
|
Glaukos Corp | Series D | ||||
|
|
InteKrin Therapeutics Inc | Biopharmaceutical company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders.. | Series C | |||
|
|
Avanir Pharmaceuticals Inc | A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. | N/A | |||
|
|
Acceleron Pharma Inc | Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. | Series C Initial investment | |||
|
|
Enobia Pharma Corp | Series B |
Team
| Employee | Position | |||
|---|---|---|---|---|
| Nissim Darvish | ||||
| W. Carter Neild | [email protected] | |||
| William Sawyer | ||||
| Trevor Polischuk |